Johnson & Johnson has ended its phase 3 development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease.
The clinical research specialist's subsidiary Jannssen Alzheimer Immunotherapy (Janssen Al) is a partner with Pfizer in the Alzheimer’s Immunotherapy Program (AIP), and the AIP's joint steering committee decided to discontinue the work.
Husseini K Manji, global therapeutic area head for neuroscience at Janssen Research & Development, said: "Janssen remains strongly committed to tackling the enormous unmet medical needs in Alzheimer’s disease. We believe the trial results will provide a rich data set that will advance our understanding of this complex disease and inform future research in this field."
However, Mr Manji admitted that the company was disappointed with the results of the two bapineuzumab IV studies.
His comments came after Johnson & Johnson bought Synthes in a bid to further its clinical studies.
The company was purchased for $19.7 billion (£12.55 billion) in cash and stock.